UPDATE 2-Pfizer gets U.S. approval for $225,000 a year heart drug
May 06, 2019 at 10:22 AM EDT
The U.S. Food and Drug Administration on Monday approved Pfizer Inc's oral drug, tafamidis, to treat a rare and fatal heart disease called transthyretin amyloid cardiomyopathy, the U.S drugmaker said.